Case Presentation:
A 67‐year‐old white male with metastatic castration‐resistant prostate cancer presented to our institution with complaints of progressive generalized weakness and muscle cramps. His history included obstructive nephropathy requiring a chronic Foley catheter. Six months prior to presentation, he was admitted to the hospital with new onset lower extremity weakness. He was then found to have cord compression at the T7‐T8 spine, which was thought to be due to his known osseous metastases. Following his emergent laminectomy, he was started on denosumab, abiraterone and continued on goserelin. Before administration of denosumab, patient’s serum total calcium was 8.8mg/dL, albumin 3.8 g/dL, BUN 45mg/dL and creatinine 1.04mg/dL (CKD Epi‐eGFR 73.9mL/min). Subsequent doses of denosumab were given monthly with last known dose given 37 days prior to presentation. Current medications included calcium carbonate 1250mg daily, ergocalciferol 50,000units weekly, tamsulosin, furosemide, pantoprazole, and prednisone. On examination, significant neuromuscular irritability was present including Chvostek’s and Trousseau’s signs. ECG showed a prolonged QTc interval of 518ms compared to previous 468ms. Laboratory studies showed serum calcium of 4.8mg/dL, albumin 3.6g/dL, BUN 63mg/dL, Creatinine 2.67mg/dL (CKD‐EPI‐eGFR 23.5mL/min), PTH 118pg/ml, and 25‐hydroxy VitaminD 24.2ng/ml. Patient was diagnosed with denosumab‐induced severe hypocalcemia in the setting of acute on chronic kidney disease from worsening obstructive nephropathy. He was treated with total 26 grams of IV calcium gluconate along with calcium acetate, calcitriol, cholecalciferol and calcium carbonate. Furosemide was also switched to hydrochlorothiazide. Improvement of calcium began after thirteen days of aggressive treatment during which creatinine had modestly improved after bilateral nephroureteral catheter was placed.
Discussion:
Denosumab, a human monoclonal antibody, is a receptor activator of nuclear factor kappa‐B (RANK) ligand inhibitor, which decreases osteoclast activity. It is a novel therapy for osteoporosis and prevention of skeletal‐related events in metastatic disease. Hypocalcemia is a known side effect, particularly in those with renal dysfunction. However severity is generally mild. Hypocalcemia generally does not occur in healthy patients due to compensatory mechanisms including increases in PTH, renal reabsorption, gastrointestinal absorption, and osteoclastic activity. Patients with CKD may be predisposed to hypocalcemia as their calcium homeostasis may be more dependent on PTH‐mediated bone turnover which is inhibited by denosumab. A post‐market literature search revealed four case reports of prolonged hypocalcemia in patients following a dose of denosumab. Of these cases, two had normal renal function, one had stage 3 CKD, and the last had stage 5 CKD undergoing hemodialysis. All cases required aggressive calcium correction. Return to normocalcemia did not occur for more than one month in some cases, potentially due to denosumab’s long half‐life.
Conclusions:
Patients with renal impairment have the potential to develop prolonged life threatening hypocalcemia following treatment with denosumab. Therefore physicians will need to be more aware of this possibilty, especially with the increased utilization of denosumab.